NASDAQ: MIRAMira Pharmaceuticals Inc Stock
$0.93-0.01 (-1.06%)
Updated Jun 15, 2026
MIRA Price
$0.93
Fair Value Price
$0.27
Market Cap
$39.16M
52 Week Low
$0.90
52 Week High
$2.45
P/E
-0.73x
P/B
4.19x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.81M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.01
Operating Cash Flow
-$4M
Beta
1.68
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MIRA Overview
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MIRA's potential to beat the market
- MIRA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
MIRA
RankedUnranked of 16
RankedUnranked of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $1,129.35 | A | |
| $177.27 | B | |
| $56.24 | B |
Be the first to know about important MIRA news, forecast changes, insider trades & much more!
MIRA News
Overview
Due Diligence Score
–
Industry Average (37)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MIRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MIRA ($0.93) is overvalued by 247.93% relative to our estimate of its Fair Value price of $0.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MIRA ($0.93) is not significantly undervalued (247.93%) relative to our estimate of its Fair Value price of $0.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MIRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MIRA due diligence checks available for Premium users.
Valuation
MIRA fair value
Fair Value of MIRA stock based on Discounted Cash Flow (DCF)
Price
$0.93
Fair Value
$0.27
Overvalued by
247.19%
MIRA ($0.93) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MIRA ($0.93) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MIRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MIRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.73x
Industry
37.18x
Market
14.3x
MIRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.19x
Industry
7.22x
MIRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MIRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.2M
Profit Margin
0%
MIRA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.5M
Liabilities
$114.8k
Debt to equity
0.01
MIRA's short-term assets ($9.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MIRA's short-term assets ($9.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MIRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
$0.0
Financing
-$330.6k
MIRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MIRA vs General Drug Manufacturer Stocks
Mira Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.